Presidential Highlight from ESMO 2024 – MediMix

Elisa Agostinetto shared a post by MediMix on LinkedIn, adding:

“At ESMO24 the practice-changing results of the HypoG-01 UNICANCER trial were presented, showing that hypofractionated RT in early BC is non-inferior to normofractionated RT, and should be standard of care.

I had the privilege to discuss these results with Dr Sofia Rivera.”

Quoting MediMix:

” Presidential Highlight from ESMO 2024!

Dr Elisa Agostinetto and Dr Sofia Rivera present key findings from the HypoG-01 UNICANCER trial on breast cancer radiotherapy:
– HF RT is non-inferior to NF RT, offering similar safety with reduced treatment time.
– These results may change practice, promoting the use of HF RT for nodal irradiation.
– Future trials will continue exploring shorter treatment regimens, such as the UK’s Fast Forward trial.

Discover these updates. For all ESMO 2024 videos, find the link in the comments!”

Source: Elisa Agostinetto/LinkedIn and MediMix/LinkedIn

Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.